Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study
- 41 Downloads
To determine the prevalence of professionally reported oral side effects of chemotherapy and the self-reported oral side effects and whether both prevalences could be related to the periodontal risk of the patients.
A cross-sectional study with patients undergoing chemotherapy treatment was carried out. Demographic, oral hygiene habits, and cancer-related data were collected while the patient was receiving the chemotherapy infusion. Patient’s oral status, measured according to the oral-assessment guide for patients in hospital environments, patient-related outcomes (PROMs), measured by a visual analogue scale, and patient’s periodontal risk were analyzed using validated questionnaires. Data was reported in means and standard deviations (SD) in quantitative variables and in counts, prevalence, and 95% confidence intervals (CI) in qualitative variables. ANOVA test and chi-squared tests were used to compare oral side effects among different periodontal risk groups.
Three hundred sixty-nine patients were included in the study. The prevalence of professionally reported oral side effects was 86.99% (95% confidence interval CI 83.54%; 90.44%). The prevalence of self-reported oral side effects was 89.70% (95% CI 86.59; 92.82). The most common oral side effects were xerostomia (73.4%), dysgeusia (61.8%), and dry lips (54.2%). More oral alterations were found in patients with worse periodontal risk (p < 0.001).
The prevalence of oral side effects (professional or self-reported) is higher than 85% in patients undergoing chemotherapy. This prevalence increases as the risk of developing periodontal disease does.
KeywordsChemotherapy Oral side effects Xerostomia Dysgeusia Periodontal risk
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
“All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.”
Informed consent was signed by all the participants in the study.
- 2.Wong HM (2014) Oral complications and management strategies for patients undergoing cancer therapy. Sci World J 2014. https://doi.org/10.1155/2014/581795
- 3.Watters A, Epstein J, Agulnik M (2011) Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol 47(6):441–448. https://doi.org/10.1016/j.oraloncology.2011.03.028 CrossRefPubMedGoogle Scholar
- 19.Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120(10):1453–1461. https://doi.org/10.1002/cncr.28592 CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Eilers J, Berger AM, Petersen M (1987) Development, testing, and application of the oral assessment guide. Oncol Nurs Forum 15(3):325–330Google Scholar
- 21.Serrano JHD (2011) Evaluación de un cuestionario para la asignación del riesgo individual del individuo en el desarrollo de las enfermedades periodontales. Periodoncia y Osteointegración 21(2):133–142Google Scholar
- 24.Jensen SB, Pedersen AML, Vissink A, Andersen E, Brown CG, Davies AN, Dutilh J, Fulton JS, Jankovic L, Lopes NN (2010) A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 18(8):1039–1060. https://doi.org/10.1007/s00520-010-0827-8 CrossRefPubMedGoogle Scholar
- 25.Mercadante S, Aielli F, Adile C, Ferrera P, Valle A, Fusco F, Caruselli A, Cartoni C, Massimo P, Masedu F (2015) Prevalence of oral mucositis, dry mouth, and dysphagia in advanced cancer patients. Support Care Cancer 23(11):3249–3255. https://doi.org/10.1007/s00520-015-2720-y CrossRefPubMedGoogle Scholar
- 26.Ponticelli E, Clari M, Frigerio S, De Clemente A, Bergese I, Scavino E, Bernardini A, Sacerdote C (2017) Dysgeusia and health-related quality of life of cancer patients receiving chemotherapy: a cross-sectional study. Eur J Cancer Care 26 (2). doi: https://doi.org/10.1111/ecc.12633
- 28.Lockhart PB, Sonis ST (1981) Alterations in the oral mucosa caused by chemotherapeutic agents. J Dermatol Surg Oncol 7(12):1019–1025. https://doi.org/10.1111/j.1524-4725.1981.tb00208.x CrossRefPubMedGoogle Scholar
- 32.Overholser C, Peterson DE, Williams LT, Schimpff SC (1982) Periodontal infection in patients with acute nonlymphocytic leukemia: prevalence of acute exacerbations. Arch Intern Med 142(3):551–554. https://doi.org/10.1001/archinte.1982.00340160131025 CrossRefPubMedGoogle Scholar
- 34.Jensen SB, Mouridsen HT, Bergmann OJ, Reibel J, Brunner N, Nauntofte B (2008) Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106(2):217–226. https://doi.org/10.1016/j.tripleo.2008.04.003 CrossRefPubMedGoogle Scholar